If you sell peptides or research compounds, you have probably already lived this: payments are flowing, then one morning Stripe, PayPal, or Square freezes the account and holds your money. It is not a glitch and it is not something you can appeal your way out of. It is a policy decision, and the fix is not another mainstream processor — it is the right high-risk merchant account, set up so it approves and, more importantly, survives.
This guide walks through why it happens, exactly what you need, the real approval criteria, and the decline reasons that sink most applications — written from what we actually see boarding these businesses.
Stripe, PayPal, and Square are payment aggregators. They onboard millions of merchants under one set of acceptable-use rules, and those rules prohibit research chemicals and unapproved supplements outright. You are usually approved instantly because nobody underwrote you individually — which is exactly why you get shut off the moment a review flags the products or a chargeback spike appears.
When that happens, their terms let them hold settled funds for up to 180 days. Re-applying to the same aggregator almost never works, because the original termination follows your business details. The category is also under active card-network scrutiny — Visa and Mastercard both tightened high-risk and supplement enforcement through 2025–2026 — so the bar is only rising.
The solution is a dedicated high-risk merchant account, individually underwritten and placed with an acquiring bank that knowingly accepts research-use-only compounds. The differences from an aggregator:
| Aggregator (Stripe/PayPal) | High-risk merchant account |
|---|---|
| Instant approval, no underwriting | Individually underwritten for your model |
| Prohibits research compounds | Boarded under MCC 8099 / research-supply codes |
| Freezes funds up to 180 days | Rolling reserve (typically 5–10%), funds released on schedule |
| Flat ~2.9% + 30¢ | 3.5–4.95% discount rate (priced for the risk) |
| No dedicated rep | A named underwriting contact who knows your file |
You pay more, and you keep your business. For most peptide sellers that trade is not close.
This is the single biggest lever. If your site is positioned as research-use-only, with explicit RUO labeling and no human-consumption or dosing language, you fit a category banks can board. The moment a site reads as therapeutic or for human use, the application moves from "high-risk approvable" to "needs LegitScript or decline."
Underwriters want to see that the products are what you say they are. Published, current COAs from a third-party lab signal a real operation and materially improve approval odds.
Whether you need LegitScript certification depends entirely on how you sell. RUO sellers with clean labeling can often board without it. Anything resembling human-consumption or efficacy claims will be asked for it — and getting it is slow, so position correctly from the start.
Expect a rolling reserve, commonly 5–10% held and released on a rolling schedule, and a discount rate in the 3.5–4.95% range. Reserves are normal and temporary; treat them as working-capital timing, not a loss.
| Decline reason | The fix |
|---|---|
| Missing or inconsistent RUO labeling | Label every product RUO, remove dosing/consumption language sitewide |
| No certificate of analysis | Publish current third-party COAs before applying |
| Human-consumption / efficacy claims on site | Strip therapeutic claims; research framing only |
| Business model doesn't match the live site | Make the application and the website tell the same story |
| Prior terminations disclosed late | Disclose up front — underwriters find them anyway; late disclosure kills trust |
The encouraging part: almost every one of these is fixable before you submit. Most "I keep getting declined" cases are a labeling and disclosure problem, not a fundamental one.
High-risk underwriting is more involved than pasting an API key, but it is predictable. Having the file ready up front is the difference between approval in days and a drawn-out back-and-forth. Prepare these before you apply:
| What underwriting wants | Why |
|---|---|
| Business formation docs + EIN | Confirms a real, registered entity behind the account |
| 3–6 months of prior processing statements (if you have them) | Shows real volume and your true chargeback history |
| Voided check / bank letter for settlement | Where funds land; must match the business name |
| Current third-party COAs | Proves the products are what the site claims |
| The live site URL, finalized | Underwriters review the actual site, not a staging link — fix labeling first |
With a clean file, a research-use-only peptide merchant is typically a days-not-weeks decision. The applications that stall are the ones missing COAs, pointing at a site still carrying consumption language, or disclosing a prior termination halfway through. Front-load the file and you collapse the timeline.
Getting approved is half the job. High-risk accounts get shut down after approval too — usually for the same reason aggregators cut you off: chargebacks. The card networks watch this directly. Visa's acquirer monitoring program flags merchants once disputes climb toward roughly 0.9% of transactions (and harder thresholds above that), and sustained breaches put your account — and your acquiring bank's relationship — at risk.
The merchants who keep their processing stable tend to do the same handful of things:
Stable processing in this category isn't luck. It's the right account boarded to the right model, plus disciplined dispute hygiene so you never drift toward the thresholds that trigger a shutdown.
Peptides are the sharpest version of this problem, but they are not the only vertical that gets deplatformed for reasons that have nothing to do with whether the business is legitimate. Of the 675 high-risk merchants in our pipeline, peptides are the largest single group, but the same approval-and-survival playbook applies across the 16 verticals we see — e-commerce flagged for "high chargeback potential," supplements, credit-repair, cannabis-adjacent, and other categories the aggregators simply won't keep.
The mechanics are identical everywhere: get individually underwritten by a bank that knows your model, position the business honestly so it boards clean, price the reserve and rate into your margins, and run tight dispute hygiene so you stay well under the network thresholds. Do that, and "processor shut me down" stops being a recurring emergency and becomes a solved problem.
See if your peptide business qualifies →Their acceptable-use policies prohibit research chemicals and unapproved supplements. They freeze the account on review or after chargebacks and can hold funds up to 180 days. It is a policy decision, so re-applying to the same processor rarely works.
A high-risk merchant account boarded under MCC 8099 (or a related research-supply code) with a bank that underwrites RUO compounds — usually with a 5–10% rolling reserve and a 3.5–4.95% rate.
It depends on your model. Clean RUO sellers can often board without it; human-consumption or efficacy positioning will require it or get declined.
Most often: missing RUO labeling, no COA, consumption/efficacy claims, a model-vs-site mismatch, or late-disclosed prior terminations — all fixable before re-submitting.